HeartSciences Temettü

Temettü kriter kontrolleri 0/6

HeartSciences şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.7%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$7.98
Gelecekteki Temettü Verimi	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

HeartSciences granted U.S patent for ECG assessment of heart

Sep 20

Heart Test Laboratories reports Q1 results

Sep 13

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: HSCS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: HSCS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

HeartSciences Piyasaya Karşı Temettü Getirisi

HSCS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (HSCS)	n/a
Pazarın Alt %25'i (US)	1.5%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Medical Equipment)	1.7%
Analist tahmini (HSCS) (3 yıla kadar)	n/a

Önemli Temettü: HSCS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, HSCS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: HSCS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: HSCS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

HeartSciences Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Heart Test Laboratories, Inc., Annual General Meeting, Nov 07, 2024

Heart Test Laboratories, Inc. announced that it has received $1.9 million in funding

Heart Test Laboratories, Inc. Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction

Nasdaq to Delist Heart Test Laboratories Securities from Nasdaq Capital Market

Nasdaq to Delist Heart Test Laboratories Securities from Nasdaq Capital Market

Forecast to breakeven in 2027

HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Third quarter 2024 earnings released: US$0.031 loss per share (vs US$0.16 loss in 3Q 2023)

Heart Test Laboratories, Inc. Appoints Partho P. Sengupta to Its Scientific Advisory Board

Heart Test Laboratories, Inc. Appoints Jordan B. Strom to Its Scientific Advisory Board

HeartSciences Appoints Benjamin Glicksberg to its Scientific Advisory Board

Nasdaq Grants Extension to Heart Test Laboratories to Regain Compliance

Heart Test Laboratories, Inc., Annual General Meeting, Feb 15, 2024

Price target decreased by 77% to US$0.90

Heart Test Laboratories, Inc., Annual General Meeting, Jan 17, 2024

Heart Test Laboratories, Inc., Annual General Meeting, Jan 17, 2024

Heart Test Laboratories, Inc. announced that it has received $1.085006 million in funding

New major risk - Shareholder dilution

Heart Test Laboratories, Inc. announced that it has received $1 million in funding

First quarter 2024 earnings released: US$0.13 loss per share (vs US$0.28 loss in 1Q 2023)

Heart Test Laboratories, Inc. announced that it expects to receive $1 million in funding

Heart Test Laboratories Receives Decision from Panel Granting Company’s Request for Continued Listing on Nasdaq Capital Market, Subject to Company Demonstrating Compliance with Equity Rule on or Before November 21, 2023

Heart Test Laboratories, Inc. Announces Further Expansion of Artificial Intelligence Patent Portfolio

Heart Test Laboratories Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 9.2% to US$3.75

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 142%

Third quarter 2023 earnings released

Heart Test Laboratories, Inc. Announces Executive Changes

Heart Test Laboratories Receives Letter from the Nasdaq

Second quarter 2023 earnings released

Heart Test Laboratories, Inc.'s MyoVista Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events

Heart Test Laboratories, Inc. Receives Patent from the European Patent Office

Heart Test Laboratories, Inc. Announces Major Milestone with the Issuance of CPT Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction

Heart Test Laboratories, Inc. Granted U.S Patent for ECQ Assessment of Heart Diastolic Function Using Artificial Intelligence

HeartSciences granted U.S patent for ECG assessment of heart

Heart Test Laboratories, Inc. to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital

Heart Test Laboratories reports Q1 results

Heart Test Laboratories, Inc. has completed an IPO in the amount of $6.375 million.

Heart Test Laboratories, Inc. has completed an IPO in the amount of $6.375 million.

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin